The FDA is signaling a more flexible approach to evaluating psychedelic drugs, while still keeping its core scientific standards intact.
In April 2026, the agency issued National Priority Vouchers to three psychedelic drug developers, including companies studying psilocybin for depression and a methylone-related compound for PTSD.
The FDA also allowed an early-phase U.S. clinical study of an ibogaine-based drug for alcohol use disorder to proceed, marking a notable first for that substance.
In July 2026, the FDA finalized guidance for psychedelic clinical trials, laying out design issues such as functional unblinding, placebo choices, expectancy effects, and durability of benefit.
The agency scheduled a public hearing for September 14, 2026, to gather input on the potential future therapeutic use of psychedelic drugs.
The broader regulatory push follows a White House executive order directing federal agencies to accelerate research, review, and possible access pathways for certain psychedelic therapies, especially for serious mental illness and veterans.
Sources:
Potential Future Therapeutic Use of Psychedelic Drugs ...
FDA moves to fast-track review of psilocybin and methylone for mental health | CNN
FDA Psychiatry Roundup: April 2026
FDA plans ultra-fast review of three psychedelic drugs following Trump directive
FDA's New Psychedelic Drug Guidance Paves a Path to ...
FDA fast-tracks review of new psychedelic mental health ...
The FDA Is Finally Asking the Public What It Thinks About ...
FDA criticism of MDMA-assisted therapy is an ... - STAT News
FDA fast-tracks the development of psychedelic ...
FDA Finalizes Psychedelic Trial Rules: Unblinding Problem Gets Official Answer
Considerations for Potential Future Therapeutic Use of ...
Accelerating Medical Treatments for Serious Mental Illness
FDA Issues First Draft Guidance on Clinical Trials with ...
The FDA Finally Wrote Rules for Psychedelic Trials. Now It Wants to ...